Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.
$400 million fixed rate notes, due November 2027, bearing interest at a rate of 3.75%. $500 million floating rate notes, due No...
Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth expe...
Guidance unchangedIn 2025, sales are anticipated to grow by a high single-digit percentage at CER. Sanofi confirms the expectat...
Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.60 by 6.31 p...
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp...
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi ...
